Wednesday, October 20, 2010

HCV Morning News

Morning News

Adiponectin Shows Potential In Blocking Obesity-Related Carcinogenesis
20 October 2010A research team from Emory University School of Medicine investigated the role between adiponectin and leptin in obesity-related carcinogenesis. Their findings, published in the November issue of Hepatology, suggest that the...
[read article]


Blood transfusion scandal: 4,670 British haemophiliacs were left infected with Hepatitis C, of whom 1,243 were also infected with HIV
A woman writes:"In 2008, my husband was diagnosed with hepatitis C. In 2009, he underwent a 48-week treatment for it. Treatment took a toll on him. He got all of its side effects. Six months after treatment was completed, the doctor told him that the treatment didn’t work. She said that some things in the works might be available in a couple of years"
$7.5M grant to fund research on interaction of drinking and HIV infection
PROVIDENCE, R.I. [Brown University] — Living with HIV is difficult under the best of circumstances, but for people carrying the virus, alcohol consumption can become particularly perilous in intricate ways that are only beginning to be understood. At the Brown Alcohol Research Center on HIV (ARCH) funded by a new $7.5-million, five-year grant from the National Institutes of Health, Brown University scientists will study the health effects of drinking with HIV and provide doctors and patients with the latest guidance their results suggest.
Switching antiretroviral treatment from efavirenz or AZT was associated with an improvment in vitamin D levels, investigators report in the online edition of AIDS Research and Human Retroviruses. Calendar month and black race were also associated with vitamin deficiency.

Study Finds
ScienceDaily (Oct. 19, 2010) — Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score -- a new index of adipose dysfunction -- has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).

HEPATOLOGY: Ameliorating scarring of the liver
Chronic liver damage, such as that caused by chronic infection with hepatitis C virus or by chronic alcohol abuse, leads to scarring of the liver tissue (a condition also known as liver fibrosis) and ultimately end-stage liver disease. A team of researchers, led by Hermann Wasmuth, at University Hospital Aachen, Germany, has now found a way to ameliorate experimental liver fibrosis in mice.

TITLE: Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice
AUTHOR CONTACT: Hermann E. Wasmuth University Hospital Aachen, Aachen, Germany. Phone: 49.241.8080861; Fax: 49.241.8082455; E-mail:
View this article at:

No comments:

Post a Comment